Comparing Paclitaxel Poliglumex and Docetaxel for Lung Cancer Treatment
Author Information
Author(s): Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, García-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld A J, Oldham F B, Bandstra B, Singer J W, Bonomi P
Hypothesis
Does paclitaxel poliglumex provide similar survival outcomes to docetaxel in second-line treatment for non-small-cell lung cancer?
Conclusion
Paclitaxel poliglumex and docetaxel produced similar survival results but had different toxicity profiles.
Supporting Evidence
- Median survival was 6.9 months in both treatment arms.
- Patients receiving PPX had less febrile neutropenia and alopecia.
- 34% of patients in the PPX arm discontinued due to adverse events compared to 16% in the docetaxel arm.
- Grade 3 or 4 neuropathy was more common in the PPX arm.
Takeaway
This study looked at two treatments for lung cancer and found that they worked about the same, but one had fewer side effects.
Methodology
A phase III trial comparing overall survival in patients treated with paclitaxel poliglumex versus docetaxel.
Potential Biases
Potential bias due to open-label design.
Limitations
The study did not achieve noninferiority for paclitaxel poliglumex compared to docetaxel.
Participant Demographics
72% male, 92% Caucasian, median age 61 years.
Statistical Information
P-Value
P=0.257 for median survival, P=0.134 for one-year survival, P<0.001 for adverse events.
Confidence Interval
95% CI=0.94–1.27
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website